Clinical Study Shows Kratom Modestly Increases CYP3A Drug Metabolism; Implications for Drug Interactions Emerging

Why it matters

First clinical pharmacokinetic study demonstrates that kratom can alter how the body processes medications, increasing systemic drug exposure. This finding is critical for clinicians managing patients on multiple medications who use kratom.

The big picture

Kratom alkaloids interact with cytochrome P450 enzymes (CYP) that metabolize most medications. While this study shows modest CYP3A effects, kratom inhibits multiple CYP pathways at varying degrees. Combined with polydrug use patterns observed in kratom users, drug interactions present a significant but underrecognized clinical risk.

Key findings

• A single low dose of kratom can increase systemic exposure to co-consumed drugs undergoing CYP3A metabolism
• Moderate CYP3A inhibition observed; sufficient to warrant clinical monitoring in polypharmacy patients
• Previous in vitro evidence suggested stronger CYP2D6 and CYP3A inhibition; clinical results validate concern but suggest variable individual response
• No severe adverse events reported in the study, but many kratom users combine kratom with opioids, sedatives, and psychotropic medications
• Dose-dependent effects likely; higher kratom doses expected to produce stronger enzymatic inhibition

What they say

"Results suggest that a single low dose of kratom can modestly increase systemic exposure to co-consumed drugs that undergo extensive intestinal and hepatic CYP3A metabolism." — Clinical Pharmacology & Therapeutics

Bottom line

**Kratom users on medications should consult clinicians; even modest CYP3A effects combined with polydrug use could elevate adverse event risk in vulnerable populations.**